Qlucore to Expand its Marketing Efforts with New High-profile Appointment to its Board
News Nov 25, 2009
Qlucore has appointed Pia Gideon, the former Vice President of Marketing and Communication at Ericsson, to its Board of Directors.
“Qlucore is now ready for the next phase of expansion, and we are thrilled to have Pia Gideon joining us, as we know that Qlucore will benefit from her extensive experience in global marketing and communications,” says Cecilia Schelin Seidegård, Chairman of the Board.
Qlucore is best known for its highly intuitive Qlucore Omics Explorer product, which enables instant analysis and adds increased creativity to research, thanks to the software's impressive speed and statistical capability. Qlucore was founded in 2007 and has already delivered its solutions to leading research organisations and pharmaceutical companies all over the world.
Qlucore is a privately-owned company in which the founders and management hold a substantial portion of the shares. The company has today confirmed that it has raised 1,3 MSEK (approx. £115,000) in fresh capital which will be used to intensify its sales and marketing efforts.
Computer Program Helps Find Ways to Repurpose Existing DrugsNews
Researchers have developed a computer program to find new indications for old drugs. The computer program, called DrugPredict, matches existing data about FDA-approved drugs to diseases, and predicts potential drug efficacy.READ MORE
Machine Learning: Helping Determine How a Drug Affects the BrainNews
Machine learning could improve our ability to determine whether a new drug works in the brain, potentially enabling researchers to detect drug effects that would be missed entirely by conventional statistical tests, finds a new UCL study published today in Brain.READ MORE
Virus vs Human: Gene Similarities Offer Cellular Defense InsightsNews
Scientists have found that a key similarity between our genes and those of many viruses—a way of spelling out the genetic code – has likely allowed viruses to evade our cellular defenses. The research offers insight into novel avenues for vaccine development.READ MORE